Clinical Article
This retrospective study by Jain et al aimed to assess the use of atypical antipsychotics as first add-on treatment vs later add-on treatment in patients with MDD and to evaluate the potential impact of atypical antipsychotic line of therapy (LOT) on healthcare resource utilization (HCRU).
This website is intended for healthcare professionals inside the United States.
Please confirm that you are a healthcare professional inside the US.
Links to sites outside of NP Psych Navigator are provided as a resource to the viewer. AbbVie Inc accepts no responsibility for the content of non-AbbVie linked sites.
Redirect to: